Sarcoidosis
Conditions
Keywords
sarcoidosis, mycobacteria, cutaneous lesions
Brief summary
Growing research from independent laboratories provide an association between mycobacteria and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses to mycobacteria virulence factors. The purpose of this study is to assess if administration of anti-mycobacterial drug therapy will aid in resolution of cutaneous sarcoidosis lesions.
Detailed description
Independent molecular and immunologic investigations strengthen the association between mycobacterial antigens and sarcoidosis pathogenesis. Molecular analysis of sarcoidosis granulomas reveals the presence of Mycobacterium tuberculosis complex (MTB) DNA and proteins that are significantly absent from granulomatous controls. Mycobacterial DNA has been detected in cutaneous sarcoidosis lesions, in addition to systemic immune responses against mycobacterial antigens. Due to the association between sarcoidosis and mycobacterial antigens, we postulated that broad spectrum antimycobacterial therapy could lead to restoration of T cell function and clinical improvement of chronic cutaneous sarcoidosis lesions. We investigated the safety and efficacy of Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin (CLEAR) therapy among chronic cutaneous sarcoidosis subjects, with change in lesion diameter from baseline to completion of 8 weeks of therapy as the primary endpoint; we assessed for decreases in granuloma burden, if granulomas were evident upon histologic examination. Change in modified Sarcoidosis Activity Severity Index (SASI) was the secondary endpoint.
Interventions
Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
DRUGPlacebo Regimen
lactose control tablets; one for each antibiotic with equivalent pills
Sponsors
Vanderbilt University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, biopsy finding granulomas, and no alternative for the cause of the granulomas, such as tuberculosis 2. Patients must have chronic cutaneous skin lesions with or without taking chronic therapy (corticosteroids, methotrexate (max 10mg/week), azathioprine, hydroxychloroquine, cyclophosphamide, minocycline, doxycycline and chloroquine), in which the dose has not been altered in the 2 months prior to starting the study. 3. Subject has a diagnosis of cutaneous sarcoidosis for greater than 6 months with a Sarcoidosis Activity and Severity Index assessment score of at least 4. Diagnosis can be made by either: * Skin lesions characteristic of sarcoidosis and a biopsy showing granulomas with no evidence of mycobacteria, fungus, or malignancy. * A biopsy that does not show granulomas, but the patient has characteristic skin lesions and history of clinical features suggesting sarcoidosis (previous biopsy revealing noncaseating granuloma, bilateral hilar adenopathy, erythema nodosum, uveitis, raised ACE level, BAL lymphocytosis (CD4:CD8\>3.5), panda/lambda sign on gallium scan) * Accepted clinical variants include, but are not necessarily limited to the following: * lupus pernio * nodular * subcutaneous * annular * angiolupoid * plaque * papular * lichenoid * psoriasiform * For purposes of this study moderate to severe cutaneous sarcoidosis is defined as the presence of sarcoidal skin lesions with any of the following features: * At least 5 easily visible facial lesions, or * Disease which involves \> 3% BSA, or * Disease which confers functional impairment (e.g. nasal or visual field obstruction), or * Disease which confers significant symptoms of itching and/or pain. 4. If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is using one of the following methods of birth control for the duration of the study and 90 days after study completion: * condoms, sponge, foams, jellies, diaphragm, or intrauterine device * contraceptives (oral or parenteral) for three months prior to study drug administration * a vasectomized sole partner * Females of childbearing potential must have a negative serum pregnancy test at screening visit.
Exclusion criteria
1. No consent/inability to obtain consent. 2. Age less than 18 years of age. 3. Inability to obtain biopsy or draw blood. 4. CPK, ALT or AST \>5 times upper limit of normal (ULN) 5. Pregnancy or breast feeding. 6. Current use of medications metabolized by rifampin (See Appendix). 7. Allergy to macrolides, quinolones or rifamycins. 8. Visual Impairment as defined by differentiating colors. 9. Family or personal history of long QT syndromes. 10. Patients receiving another interventional investigational drug within the 30 days prior to dosing 11. Use of any investigational medication within the past 28 days prior to study enrollment. 12. Subject has been hospitalized for infection or received IV antibiotics within the previous 2 months prior to baseline. 13. Subject has a history of tuberculosis at anytime or close contact with a person with active tuberculosis within the previous 6 months, or persistent or active infections requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or antifungals for purpose of treating infection, within 14 days of baseline. 14. Evidence of other active skin diseases or skin infections during screening that may interfere with evaluation of sarcoidosis. 15. Subject has an active infection requiring systemic antibiotics at time of screening 16. Subject has a history of listeriosis, treated or untreated tuberculosis, exposure to individuals with tuberculosis. 17. Subject has a variant of sarcoidosis that is not amenable to study evaluation, in the absence of chronic indurated lesions, such as: * Acute, benign sarcoid associated with erythema nodosum * Acute iritis * Ichthyosiform sarcoidosis * Hypo- or hyperpigmented macular sarcoidosis * Ulcerative sarcoidosis * Erythroderma * Alopecia 18. Patients otherwise unsuitable for participation in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions | Baseline to 8 weeks | — |
| Granuloma Burden | Baseline to 8 weeks | Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy. | Baseline to 8 weeks | Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe). |
Countries
United States
Participant flow
Pre-assignment details
One patient who was randomized to the CLEAR regimen did not have lesions compatible with sarcoidosis at baseline. This patient did not proceed with study participation and was removed from number of patients that started the study.
Participants by arm
| Arm | Count |
|---|---|
| Antibiotics This study will compare the effects of antibiotics or placebo on resolution of cutaneous sarcoidosis lesions. | 14 |
| Lactose Tablets Patients who are randomized to control arm will receive an equivalent number of lactose tablets. | 15 |
| Total | 29 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 3 | 3 |
| Overall Study | Lost to Follow-up | 0 | 1 |
Baseline characteristics
| Characteristic | Antibiotics | Lactose Tablets | Total |
|---|---|---|---|
| Age, Continuous | 55 years | 53 years | 53 years |
| Gender Female | 9 Participants | 10 Participants | 19 Participants |
| Gender Male | 5 Participants | 5 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 3 / 15 | 3 / 15 |
| serious Total, serious adverse events | 0 / 15 | 0 / 15 |
Outcome results
Primary
Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions
Time frame: Baseline to 8 weeks
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Antibiotic Regimen | Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions | -8.4 mm | Standard Deviation 14 |
| Placebo Regimen | Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions | 0.07 mm | — |
Primary
Granuloma Burden
Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy)
Time frame: Baseline to 8 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Antibiotic Regimen | Granuloma Burden | 7 participants |
| Placebo Regimen | Granuloma Burden | 0 participants |
Secondary
Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy.
Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe).
Time frame: Baseline to 8 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Antibiotic Regimen | Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy. | -2.9 units on a scale | Standard Deviation 2.5 |
| Placebo Regimen | Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy. | -0.6 units on a scale | Standard Deviation 2.1 |